Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-infusion VAY736 vs placebo in relapsing-remitting multiple sclerosis
2013-002324-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in multiple sclerosis (MS) comparing VAY736 single infusion with Placebo infusion (2 arms). Primary endpoint: Cumulative number of new gadolinium-enhancing brain MRI lesions. Started Jan 2014; status: completed.
02
Drugs
ianalumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-002324-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002324-16.